Publication:
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

Simple item page
dc.contributor.authorYAŞAR, ALPER
dc.contributor.authorBAYOĞLU, İBRAHİM VEDAT
dc.contributor.authorsKAHRAMAN S., ERUL E., Seyyar M., GÜMÜŞAY Ö., Bayram E., Demirel B. C., Acar O., AKSOY S., Baytemur N. K., ŞAHİN E., et al.
dc.date.accessioned2023-06-05T11:03:41Z
dc.date.available2023-06-05T11:03:41Z
dc.date.issued2023-03-01
dc.description.abstractBackground: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference.
dc.identifier.citationKAHRAMAN S., ERUL E., Seyyar M., GÜMÜŞAY Ö., Bayram E., Demirel B. C., Acar O., AKSOY S., Baytemur N. K., ŞAHİN E., et al., "Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer", FUTURE ONCOLOGY, cilt.19, ss.727-736, 2023
dc.identifier.doi10.2217/fon-2022-1287
dc.identifier.endpage736
dc.identifier.issn1479-6694
dc.identifier.startpage727
dc.identifier.urihttps://hdl.handle.net/11424/289925
dc.identifier.volume19
dc.language.isoeng
dc.relation.ispartofFUTURE ONCOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectSağlık Bilimleri
dc.subjectMedicine
dc.subjectInternal Medicine Sciences
dc.subjectInternal Diseases
dc.subjectOncology
dc.subjectHealth Sciences
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectONCOLOGY
dc.subjectCLINICAL MEDICINE
dc.subjectClinical Medicine (MED)
dc.subjectCDK 4
dc.subject6 inhibitors
dc.subjectHER2-negative metastatic breast cancer
dc.subjectHR-positive
dc.subjectletrozole
dc.titleTreatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
dc.typearticle
dspace.entity.typePublication
local.avesis.id6b4454d1-de76-4c63-9dab-2c0deccc7b07
local.indexed.atWOS
local.indexed.atPUBMED
local.indexed.atSCOPUS
relation.isAuthorOfPublication07d1c222-7e64-4fc6-8209-f298a813cc88
relation.isAuthorOfPublicationd4f139e7-cf36-415c-a82e-a9c7956ecede
relation.isAuthorOfPublication.latestForDiscovery07d1c222-7e64-4fc6-8209-f298a813cc88

Files

Collections

Research Outputs